Literature DB >> 28850754

Verbal memory in breast cancer patients treated with chemotherapy with doxorubicin and cyclophosphamide.

P Andryszak1, M Wiłkość1,2, B Żurawski3, P Izdebski1.   

Abstract

Memory is one of the crucial human cognitive functions, and deficits in memory processes may lead to difficulties in everyday functioning. The aim of this study was to analyse the effect of anthracycline-based adjuvant chemotherapy (AC) used in breast cancer treatment on verbal memory and learning. We also evaluated the relationship between verbal memory and psychological, somatic and socio-demographic factors. The study was carried out on a group of 31 women with early breast cancer treated with adjuvant chemotherapy and 30 healthy controls. The patients underwent neuropsychological assessment using the Rey Auditory Verbal Learning Test at three time points: before chemotherapy, mid-chemotherapy and post-chemotherapy. The examination in the controls was conducted at the same time intervals. We found an association between AC-schema chemotherapy and deficits in delayed memory. A deterioration in performance after treatment was observed in 19% of patients. The results showed no deterioration of immediate memory or the verbal learning process. Moreover, a positive relationship was shown between the level of education, physical fitness and the functioning of verbal memory. The results of the study also indicate that age and hormonal status are factors that may increase the possibility of deficits in verbal memory after AC-schema chemotherapy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  AC chemotherapy; breast cancer; cognition; learning; oncology; verbal memory

Mesh:

Substances:

Year:  2017        PMID: 28850754     DOI: 10.1111/ecc.12749

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  5 in total

Review 1.  Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights.

Authors:  Jiajia Du; Aoxue Zhang; Jing Li; Xin Liu; Shuai Wu; Bin Wang; Yanhong Wang; Hongyan Jia
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

2.  The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2-/+ Breast Cancer.

Authors:  Wen Li; Qianqian Zhang; Yinlian Cai; Tingting Chen; Huaidong Cheng
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

3.  Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis.

Authors:  Alexandra L Whittaker; Rebecca P George; Lucy O'Malley
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

4.  Piperlongumine as a Neuro-Protectant in Chemotherapy Induced Cognitive Impairment.

Authors:  Fabio Ntagwabira; Madison Trujillo; Taylor McElroy; Taurean Brown; Pilar Simmons; Delawerence Sykes; Antiño R Allen
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

5.  Catechol-O-Methyltransferase Gene Polymorphisms and the Risk of Chemotherapy-Induced Prospective Memory Impairment in Breast Cancer Patients with Varying Tumor Hormonal Receptor Expression.

Authors:  Wen Li; Jingjing Zhao; Ke Ding; Herta H Chao; Chiang-Shan R Li; Huaidong Cheng; Li Shen
Journal:  Med Sci Monit       Date:  2020-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.